生物制药的接力创新与风险传导特性研究  

Relay Innovation and the Characteristics of the Risk Transmission in Bio-pharmaceutical Industry

作　　者：李天柱[1,2] 马佳[1] 冯薇[2] 梁萌萌[1] 

机构地区：[1]辽宁科技大学工商管理学院,辽宁鞍山114051 [2]电子科技大学经济与管理学院,四川成都610054

出　　处：《科技促进发展》2013年第4期62-69,共8页Science & Technology for Development

摘　　要：生物制药创新面临巨大的风险,管理生物制药的创新风险必须从其创新特性入手。基于生物制药的接力创新模式,针对"发现"、"大学-专家型公司"接力"、转化""、专家型公司-核心公司"接力"、实现"等主要环节归纳其典型创新风险,在此基础上引入"中间风险"的概念,并分析风险的关联和传导效应,进一步揭示生物制药创新风险的特性。最后针对政府主管部门的分析,提出管控生物制药安全风险的思路。The bio-pharmaceutical innovation has been confronted with huge risk, which must be managed from the aspects of innovation characteristics. Based on the relay innovation patterns in bio-pharmaceutical industries, the typical innovation risks in main steps are researched in sequence, proceeding from discovery, University-expert company relay, transformation, expert company-core company relay, to realization. On these bases, the concept of intermediate risk has been defined, and the relevancies and conductive effects among innovation risks are analyzed, which makes further efforts on revealing the characteristics of bio-pharmaceutical innovation risks. In the end, the specific thinking for the government drug safety risk management and control are presented.

关 键 词：生物制药 创新风险传导 接力创新 中间风险 

分 类 号：F426.72[经济管理—产业经济] F273.1